| |
|
|
|
| deaths (OS) | progression or deaths (PFS) | RFS/DFS |
mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population |
|
| pembrolizumab alone vs. placebo | 1 | - | - | 0.57 [0.43; 0.75], 1 RCT, I2=0% conclusive
unassessable degree of certainty |
mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive |
|
| pembrolizumab alone vs. placebo | 1 | - | - | 0.54 [0.42; 0.69], 1 RCT, I2=0% conclusive
unassessable degree of certainty |
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population |
mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant |
mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild |
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population |
|
| pembrolizumab (10mg/kg) vs. ipilimumab alone | 1 | 0.69 [0.52; 0.91], 1 RCT, I2=0% conclusive
unassessable degree of certainty | 0.58 [0.47; 0.72], 1 RCT, I2=0% conclusive
unassessable degree of certainty | - |
| pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab alone | 1 | 0.63 [0.47; 0.84], 1 RCT, I2=0% conclusive
unassessable degree of certainty | 0.58 [0.46; 0.73], 1 RCT, I2=0% conclusive
unassessable degree of certainty | - |
|
| pembrolizumab (10mg/kg) vs. Standard of Care (SoC) | 1 | 0.74 [0.57; 0.96], 1 RCT, I2=0%
unassessable degree of certainty | 0.50 [0.39; 0.64], 1 RCT, I2=0% conclusive
unassessable degree of certainty | - |
| pembrolizumab (2mg/kg) vs. Standard of Care (SoC) | 1 | 0.86 [0.67; 1.10], 1 RCT, I2=0%
inconclusive result | 0.57 [0.45; 0.73], 1 RCT, I2=0% conclusive
unassessable degree of certainty | - |
mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant |
|
| pembrolizumab plus SoC vs. placebo plus SoC | 1 | 0.76 [0.41; 1.40], 1 RCT, I2=0%
inconclusive result | 0.66 [0.40; 1.08], 1 RCT, I2=0%
inconclusive result | - |
